Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

INTRODUCTION: The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with the standard 10 mg/day dose. Results from this study indicated that afte...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ferris, Steven, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Sabbagh, Marwan, Liu, Liang, Mackell, Joan, Fain, Randi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2013
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4055003/
https://ncbi.nlm.nih.gov/pubmed/23433097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt166
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg